ClinicalTrials.gg
Sign In
Drug

Flortaucipir clinical trials

Also written 18F-AV-1451, LY3191748 and Tauvid.

studies test it
32
open now
6
in phase 3
4
first study started
2013

How each study uses flortaucipir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the flortaucipir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
22 Aug 2024 · Tauvid · EMEA/H/C/006064 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Flortaucipir F18
18
[F-18]T807
15
F-18 AV 1451
3
[F18]T807
2
[18F]T807
2

Brand

Tauvid
9

Development codes

18F-AV-1451
24
LY3191748
14
T807
3
ELI-101
1

Studies by the year they started

32 studies that test it; most in 2014 (6)

Studies that test flortaucipir, by start year
YearStudies
20133
20146
20156
20166
20174
20182
20193
20201
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
15
Phase 2
9
Phase 3
4
Phase 4
2
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Alzheimer Disease
22
Frontotemporal Dementia
2
Supranuclear Palsy, Progressive
2
Aphasia, Primary Progressive
1
Cognition Disorders
1
Chronic Traumatic Encephalopathy
1
Brain Injuries, Traumatic
1

Who runs them

Industry 21 · Other 11

Avid Radiopharmaceuticals (20) · Mayo Clinic (5) · Molecular NeuroImaging (2) · University of Southern California (1) · Columbia University (1) · University of Alabama at Birmingham (1) · Eli Radiopharma (1) · Tammie L. S. Benzinger, MD, PhD (1)

Often tested with

Tested in the same studies.

Florbetapir (1) · Pittsburgh compound B (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test flortaucipir.

Studies

Open first, then newest update. How each study uses flortaucipir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 32

See all 32 studies that test flortaucipir →

Given beside what is tested · 3 — flortaucipir is usual care or a partner of the new treatment

Codes

What other systems call flortaucipir · ClinicalTrials.gg INT000055

  • MeSH (NLM) C0005910087-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) J09QS3Z3WBFLORTAUCIPIRConfirmed NLM, Wikidata
  • RxNorm 2571858One source FDA
  • Wikidata Q27280989flortaucipirConfirmed NLM, Wikidata
  • DrugBank DB15033One source Wikidata

Also registered as flortaucipir f-18 (UNII T1JP1KYU9O · RxNorm 2372689).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.